Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Саркомы костей

Список литературы

  1. Алиев М.Д. Злокачественные опухоли костей. Саркомы костей, мягких тканей и опухоли кожи 2010;2:3–8.
  2. Malawer M.M., Helman L.J., O’Sullivan B. Sarcomas of bone. In: DeVita V.T., Hellman S., Rosenberg S.A. Cancer: Principles & Practice of Oncology. 8thedn. Vol. 2. 2008. Pp. 1794–1833.
  3. Kalra S., Grimer R.J., Spooner D. et al. Radiation-induced sarcomas of bone: factors that affect outcome. J Bone Joint Surg Br 2007;89(6):808–13.
  4. АлиевМ.Д., СушенцовЕ.А. Cовременная онкоортопедия. Саркомы костей, мягких тканей и опухоли кожи 2012;4:3–10.
  5. Тепляков В.В., Карпенко В.Ю., Бухаров А.В., Державин В.А., Урлова А.Н., Рубцова Н.А. Результаты хирургического лечения пациентов с метастазами в длинные трубчатые кости. Саркомы костей, мягких тканей и опухоли кожи 2010;3:10–15.
  6. Алиев М.Д. Эндопротезирование как основа онкоортопедии. Саркомы костей, мягких тканей и опухоли кожи 2010;4:7–12.
  7. La TH, Meyers PA, Wexler LH, et al. Radiation therapy for Ewing"s sarcoma: results from Memorial Sloan-Kettering in the modern era. Int J Radiat Oncol Biol Phys 2006; 64:544.
  8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Bone Cancer Version 1.2020
  9. Gogna A., Peh W.C., Munk P.L. Image-guided musculoskeletal biopsy. Radiol Clin North Am 2008;46(3):455–73.
  10. Курильчик А.А., Зубарев А.Л., Кудрявцева Г.Т., Стародубцев А.Л. Интраоперационная лучевая терапия (ИОЛТ) в комбинированном лечении остеосаркомы. Саркомы костей, мягких тканей и опухоли кожи 2010;3:30–33.
  11. Fiorenza F., Abudu A., Grimer R.J. et al. Risk factors for survival and local control in chondrosarcoma of bone. JBoneJointSurgBr 2002;84:93–99.
  12. Практические рекомендации Российского общества клинической онкологии. Злокачественные опухоли. Том 11 №3s2. 2021.с-264-277
  13. BernsteinM., KovarH., PaulussenM. etal. Ewing’s sarcoma family of tumors: current management // The Oncol. – 2006– Vol.11(5). – P.503.
  14. Bernthal N.M., Federman N., Eilber F.R. et al. Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with highgrade, operable osteosarcoma. Cancer 2012;118(23):5888–93.
  15. Casey DL, Meyers PA, Alektiar KM, et al. Ewing sarcoma in adults treated with modern radiotherapy techniques. Radiother Oncol 2014; 113:248.
  16. Rödl RW, Hoffmann C, Gosheger G, et al. Ewing"s sarcoma of the pelvis: combined surgery and radiotherapy treatment. J Surg Oncol 2003; 83:154.
  17. Koontz BF, Clough RW, Halperin EC. Palliative radiation therapy for metastatic Ewing sarcoma. Cancer 2006; 106:1790.18. Kager L., Zoubek A., Pötschger U. et al. Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols. J Clin Oncol 2003;21(10):2011–8.
  18. Casali P. G. et al. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up //Annals of Oncology. – 2018. – Т. 29. – №. Supplement_4. – С. iv79-iv95.
  19. Redondo, A., Cruz, J., Lopez-Pousa, A., &Barón, F. (2013). SEOM clinical guidelines for the treatment of osteosarcoma in adults-2013. Clinical and Translational Oncology, 15(12), 1037– 1043.doi:10.1007/s12094-013-1087-0
  20. Han G. et al. Amputation versus limb-salvage surgery in patients with osteosarcoma: a meta- analysis //World journal of surgery. – 2016. – Т. 40. – №. 8.
  21. He X. et al. A meta-analysis of randomized control trials of surgical methods with osteosarcoma outcomes //Journal of orthopaedic surgery and research. – 2017. – Т. 12. – №. 1. – С. 5.
  22. Mei J. et al. Functional outcomes and quality of life in patients with osteosarcoma treated with amputation versus limb-salvage surgery: a systematic review and meta-analysis //Archives of orthopaedic and trauma surgery. – 2014. – Т. 134. – №. 11. – С. 1507-1516.
  23. Anninga J. K. et al. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? //European journal of cancer. – 2011. – Т. 47. – №. 16. – С. 2431-2445.
  24. Yu D. et al. Methotrexate, doxorubicin, and cisplatinum regimen is still the preferred option for osteosarcoma chemotherapy: A meta-analysis and clinical observation //Medicine. – 2019. – Т. 98. – №. 19.
  25. Su W. et al. Clinical efficacy of preoperative chemotherapy with or without ifosfamide in patients with osteosarcoma of the extremity: meta-analysis of randomized controlled trials //Medical Oncology. – 2015. – Т. 32. – №. 2. – С. 19.
  26. Zhang T. et al. Efficacy Comparison of Six Chemotherapeutic Combinations for Osteosarcoma and Ewing"s Sarcoma Treatment: A Network Meta‐Analysis //Journal of cellular biochemistry. – 2018. – Т. 119. – №. 1. – С. 250-259.
  27. Протоколы клинических рекомендаций поддерживающей терапии в онкологии под ред. Академика РАН М.И. Давыдова 2-е издание, 2018 год
  28. Моисеенко Е. И., Маякова С. А. Проблемы детей, излеченных от онкологических заболеваний. В кн.: «Медицинская, психологическая и социальная адаптация детей, излеченных от онкологических заболеваний». Под редакцией М.Д. Алиева. М. «Практическая медицина». 2012, с. 27-57.
  29. Грушина Т.И. «Реабилитация в онкологии: физиотерапия». М. «ГЭОТАР-Медиа». 2006, с. 134-138.
  30. Быстрова О.В., Калугина А. С., Цыбатова Е. В., Тапильская Н. И., соавт. Способы восстановления фертильности онкологических больных. Практическая онкология. 2009, № 4, с. 245-253.
  31. Бакалова А. А., Королёва Т. Ю., Психологическая помощь детям с онкологическими заболеваниями. СПб., 2006.
  32. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-425
  33. Lee FY, Mankin HJ, Fondren G, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am 1999;81:326-338. Available at: http://www.ncbi.nlm.nih.gov/pubmed/10199270.
  34. Suzuki M.,IwataT.,Ando S. at all.Predictors of long-term survival with pulmonary metastasectomy for osteosarcomas and soft tissue sarcomas. J CardiovascSurg (Torino) 2006;47:603-8.36. Katherine A Janeway, Robert Maki. Chemotherapy and radiation therapy in the management of osteosarcoma. UpToDate article, literature review current through: Jan 2018. Last updated: Nov 21, 2016).
  35. Barker L.M., Pendergrass T.D., Sanders J.E. et al. Survival after recurrence of Ewing’s sarcoma family of tumors // J.Clin.Oncol.– 2005 – Vol.23. – P.4354.
  36. Hawkins D., Barnett T., Bensinger W. et al. Busulfan, melphalan, and thiotepa with or without total marrow irradiation with hematopoietic stem cell rescue for poor$risk Ewing sarcoma family tumors // Med. Pediatr. Oncol. – 2000 – Vol.34. –P.328.
  37. Hunold A., Weddeling N., Paulussen M. et al. // Topotecan and cyclophosphamide in patients with refractory or relapsedEwing tumors // Pediatr.Blood.Cancer. – 2006 – Vol.47. – P.795.
  38. Amichetti M, Amelio D, Cianchetti M, et al. A systematic review of proton therapy in the treatment of chondrosarcoma of the skull base. Neurosurg Rev 2010;33(2):155-165.
  39. Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer 2011;117(19):4522-4530.
  40. McDonald MW, Linton OR, Shah MV. Proton therapy for reirradiation of progressive or recurrent chordoma // Int J Radiat Oncol Biol Phys. 2013. Vol. 87. P. 1107-1114.
  41. Rutz HP, Weber DC, Goitein G, et al. Postoperative spot-scanning proton radiation therapy for chordoma and chondrosarcoma in children and adolescents: Initial experience at Paul Scherrer Institute // Int J Radiat Oncol Biol Phys. 2008. Vol. 71. P. 220-225.
  42. Rombi B, DeLaney TF, MacDonald SM, et al. Proton radiotherapy for pediatric Ewing"s sarcoma: initial clinical outcomes. Int J Radiat Oncol Biol Phys 2012;82(3):1142-1148.
  43. Munzenrider JE, Liebsch NJ. Proton therapy for tumors of the skull base // Strahlenther Onkol. 1999. Vol. 175(Suppl 2). P. 57-63
  44. Zalupski M.M., Rankin C., Ryan J.R. et al. Adjuvant therapy of osteosarcoma. A Phase II trial: Southwest Oncology Group study 9139 // Cancer. – 2004, Feb. 15 – Vol.100(4). – P. 818 825
  45. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-425.
  46. Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol 2012; 23:508-516.
  47. Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol 2015;16(1):98-107.
  48. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: A report from the Children’s Oncology Group. J Clin Oncol 2012 Nov 20;30(33):4148-4154.
  49. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children"s Cancer Group Phase II Study 9457--a report from the Children"s Oncology Group. J Clin Oncol 2006;24:152- 159.
  50. Hunold A, Weddeling N, Paulussen M, et al. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors. Pediatr Blood Cancer 2006;47:795-800.
  51. Kushner BH, Kramer K, Meyers PA, et al. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med Pediatr Oncol 2000;35:468-474.
  52. Saylors RL 3rd, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. J Clin Oncol 2001;19:3463-3469.
  53. Casey DA, Wexler LH, Merchant MS, et al. Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience. Pediatr Blood Cancer 2009;53:1029-1034.
  54. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res 2004;10:840-848.
  55. Wagner LM, McAllister N, Goldsby RE, et al. Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma. Pediatr Blood Cancer 2007;48:132-139.
  56. McNall-Knapp RY, Williams CN, Reeves EN, et al. Extended phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors. Pediatr Blood Cancer 2010;54:909-915.
  57. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: a pediatric oncology group study. Clin Cancer Res 2001;7:32-37.
  58. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999;17:1815-1824.
  59. McGregor LM, Stewart CF, Crews KR, et al. Dose escalation of intravenous irinotecan using oral cefpodoxime: A phase I study in pediatric patients with refractory solid tumors. Pediatr Blood Cancer 2012;58:372-379.
  60. Reed DR, Hayashi M, Wagner L, et al. Treatment pathway of bone sarcoma in children, adolescents, and young adults. Cancer 2017;123(12):2206-2218.
  61. Raciborska A, Bilska K, Drabko K, et al. Vincristine, irinotecan, and temozolomide in patients with relaspsed and refractory Ewing sarcoma. Pediatr Blood Cancer 2013;60(10):1621-1625.
  62. Wagner LM, Perentesis JP, Reid JM, et al. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children"s Oncology Group phase I consortium study. Pediatr Blood Cancer 2010; 54(4):538-545.
  63. Navid F, Willert JR, McCarville MB, et al. Combination of gemcitabine and docetaxel in the treatment of children and young adults with refractory bone sarcoma. Cancer 2008;113:419-425.
  64. Raymond AK, Chawla SP, Carrasco CH, et al. Osteosarcoma chemotherapy effect: a prognostic factor. Semin Diagn Pathol. 1987;4:212-236
  65. Benjamin, R. S., Wagner, M. J., Livingston, J. A., Ravi, V., & Patel, S. R. (2015). Chemotherapy for Bone Sarcomas in Adults: The MD Anderson Experience. American Society of Clinical Oncology Educational Book, (35), e656–e660. doi:10.14694/edbook_am.2015.35.e656
  66. Сушенцов Е.А., Мусаев Э.Р., Маслов Л.Б., Софронов Д.И., Агаев Д.К., Дзампаев А.З., Романцова О.М., Федорова А.В., Алиев М.Д. Компьютерное моделирование, 3D-принтинг и индивидуальное протезирование в лечении больного с остеосаркомой костей таза. Саркомы костей, мягких тканей и опухоли кожи. 2019. – т.11. - №4, с.53-61
  67. JiT., GuoW., YangRL., TangXD., WangYF. Modular hemipelvic endoprosthesis reconstruction-- experience in 100 patients with mid-term follow-up results. Eur J Surg Oncol. 2013 Jan;39(1):53-60. doi: 10.1016/j.ejso.2012.10.002.70.
  68. Malawer M., Sugarbaker P. Musculoskeletal Cancer Surgery. Treatment of Sarcomas and Allied Diseases. 2001. – Springer. – p.606
  69. Sim FH, Pritchard DJ, Ivins JC. Forequarter amputation. OrthopClinNAm. 1977;8:921–31
  70. Агаев Д.К., Сушенцов Е.А., Софронов Д.И., Валиев А.К., Мусаев Э.Р., Хайленко В.А. Применение компьютерного моделирования и 3d-технологий в онкоортопедии. Обзор литературы. Саркомы костей, мягких тканей и опухоли кожи. 2019. – т.11. - №4, с.5-16
  71. Ю.В. Буйденок, А.А. Феденко, В.Ю. Буйденок, И.С. Чернов. Сосудистый доступ при современной химиотерапии местно-распространенных и генерализованных форм сарком Саркомы костей, мягких тканей и опухоли кожи. 2010 , №1 с.7-20
  72. DeLaney TF, Liebsch NJ, Pedlow FX et al. Long-term results of phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 2014; 110: 115–122.
  73. Indelicato DJ. Rotondo RL, Begosh-Mayne D, et al. A prospective outcomes study of proton therapy for chordomas and chondrosarcomas of the spine. Int J Radiat Oncol Biol Phys 2016; 95(1):297- 303.
  74. АЛГОРИТМЫ ДИАГНОСТИКИ И ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ. Сборник научных статей. Минск «Профессиональные издания» 2012. С508.
  75. Ossi, M., Anderson, E., &Freeman, A. (1996). 5-HT3 Receptor Antagonists in the Control of Cisplatin-lnduced Delayed Emesis.Oncology 1996;53(suppl 1 ):78—85
  76. Dietrich MF, et al. J Inv Med High impact Case Rep 2014;23:1–3; 2. Ebeid W, et al. EMSOS 2015: abstract FC-140;
  77. Chawla S, Henshaw R, Seeger L, et al. Safety and efficacy of Denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol 2013;14:901-8.
  78. Martin-Broto J, Cleeland CS, Glare PA, et al. Effects of Denosumab on pain and analgesic use in giant cell tumor of bone:interim results from a phase II study. Acta Oncol 2014;53:1173−9.
  79. Chawla, S., Henshaw, R., Seeger, L., Choy, E., Blay, J.-Y., Ferrari, S., Jacobs, I. (2013). Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. The Lancet Oncology, 14(9), 901–908. doi:10.1016/s1470-2045(13)70277-8.
  80. Angelini A, Drago G, Trovarelli G, Calabrò T, Ruggieri P. Infection after surgical resection for pelvic bone tumors: an analysis of 270 patients from one institution. Clin Orthop Relat Res. 2014 Jan;472(1):349-59. doi: 10.1007/s11999-013-3250-x. Epub 2013 Aug 24. PMID: 23975252; PMCID: PMC3889428.
  81. Rossi B ZC, Toma L, Ferraresi V, Biagini R. Surgical site infections in treatment of musculoskeletal tumors: Experience from a single oncologic institution. J Orthop Oncol. 2016; 2: 1-5.
  82. Тихилов, Р.М. Руководство по хирургии тазобедренного сустава / Под редакцией Р.М. Тихилова, И.И. Шубнякова // РНИИТО Санкт-Петербург. –2015. С.208—243.
  83. Fink B, Grossmann A, Fuerst M, Schäfer P, Frommelt L. Two-stage cementless revision of infected hip endoprostheses. Clin Orthop Relat Res 2009; [Epub ahead of print].
  84. Hsieh PH, Shih CH, Chang YH, Lee MS, Yang WE, Shih HN. Treatment of deep infection of the hip associated with massive bone loss. Two-stage revision with an antibiotic-loaded interim cement prosthesis followed by reconstruction with allograft. J Bone Joint Surg Br 2005;87:770-775.
  85. Ellenrieder M, Lenz R, Haenle M, Bader R, Mittelmeier W. Two-stage revision of implant- associated infections after total hip and knee arthroplasty. GMS KrankenhhygInterdiszip. 2011;6(1):Doc17. doi:10.3205/dgkh000174
  86. Tande AJ, Patel R. Prosthetic joint infection. Clin Microbiol Rev. 2014;27(2):302-345. doi:10.1128/CMR.00111-13.
  87. Gallo, J. Osteolysis around total knee arthroplasty: A review of pathogenetic mechanisms / J. Gallo, S.B. Goodman, Y.T. Konttinen, M.A. Wimmer, M. Holinka // Acta Biomater. — 2013. — Sep. — No. 9(9). — P. 8046–8058.
  88. Windisch, С. Osteodensitometry measurements of periprosthetic bone using dual energy X-ray absorptiometry following total knee arthroplasty / С. Windisch, B. Windisch, W. Kolb, K. Kolb, P. Grutzner, A. Roth // Arch Orthop Trauma Surg. — 2012. — No. 132. — P. 1595–1601.
  89. Ro DH, Jin H, Park JY, Lee MC, Won S, Han HS. The use of bisphosphonates after joint arthroplasty is associated with lower implant revision rate. Knee Surg Sports TraumatolArthrosc. 2019 Jul;27(7):2082-2089. doi: 10.1007/s00167-018-5333-4. Epub 2018 Dec 13. PMID: 30547306.
  90. Prieto-Alhambra D, Lalmohamed A, Abrahamsen B, Arden NK, de Boer A, Vestergaard P et al (2014) Oral bisphosphonate use and total knee/hip implant survival: validation of results in an external population-based cohort. Arthritis Rheumatol 66:3233–3240.
  91. Namba RS, Inacio MC, Cheetham TC, Dell RM, Paxton EW, Khatod MX (2016) Lower total knee arthroplasty revision risk associated with bisphosphonate use, even in patients with normal bone density. J Arthroplasty 31:537–541.
  92. Teng S, Yi C, Krettek C, Jagodzinski M. Bisphosphonate Use and Risk of Implant Revision after Total Hip/Knee Arthroplasty: A Meta-Analysis of Observational Studies. PLoS One. 2015 Oct 7;10(10):e0139927. doi: 10.1371/journal.pone.0139927. PMID: 26444555; PMCID: PMC4596810.
  93. Shi, Jialing et al. “Effects of bisphosphonates in preventing periprosthetic bone loss following total hip arthroplasty: a systematic review and meta-analysis.” Journal of orthopaedic surgery and research vol. 13,1 225. 4 Sep. 2018, doi:10.1186/s13018-018-0918-7.
  94. Hettwer WH, Horstmann PF, Grum-Schwensen TA, Petersen MM. Persistent wound drainage after tumor resection and endoprosthetic reconstruction of the proximal femur. Open Orthop J. 2014 Dec 29;8:475-81. doi: 10.2174/1874325001408010475. PMID: 25621083; PMCID: PMC4300510.
  95. J. Sybil Biermann. Orthopaedic Knowledge Update MusculoskeletalTumors 3: Print + Ebook. (AAOS - American Academy of Orthopaedic Surgeons). – 2018. P.20—112.
  96. Ahmad Shehadeh, Mostafa El Dahleh, Ahmed Salem, Yousef Sarhan, Iyad Sultan, Robert M Henshaw, Albert J Aboulafia. Standardization of rehabilitation after limb salvage surgery for sarcomas improves patients’ outcome. Hematol Oncol Stem Cell Ther 6(3–4) Fourth Quarter 2013. P. 105-111.
  97. Andrews CC, Siegel G, Smith S. Rehabilitation to Improve the Function and Quality of Life of Soft Tissue and Bony Sarcoma Patients. Patient Relat Outcome Meas. 2019;10:417-425. https://doi.org/10.2147/PROM.S130183.
  98. NordenC W Antibiotic prophylaxis in orthopedic surgery Rev Infect Dis Sep-Oct 1991;13 Suppl 10:S842-6 doi: 10.1093
  99. Kevin Li1, Tanmaya D Sambare, Sam Y Jiangatall Effectiveness of Preoperative Antibioticsin Preventing Su 2018 Apr;476(4):664-673. doi: 10.1007
  100. Dawn M G Rask 1, Matthew R Puntel 1, Jeanne C PatzkowskiMultivitamin Use in Enhanced Recovery After Surgery Protocols: A Cost AnalysisMil Med 2021 Aug 28;186(9-10):e1024-e1028. doi: 10.1093
  101. Rutkowski P. et al. Surgical Downstaging in an Open-Label Phase II Trial of Denosumab in Patients with Giant Cell Tumor of Bone // Ann. Surg. Oncol. 2015. Vol. 22, № 9. P. 2860–2868.
  102. Goldschlager T, Dea N, Boyd M, Reynolds J, Patel S, Rhines LD, Mendel E, Pacheco M, Ramos E, Mattei TA, Fisher CG. Giant cell tumors of the spine: has denosumab changed the treatment paradigm? J Neurosurg Spine. 2015 May;22(5):526-33. doi: 10.3171/2014.10.SPINE13937. Epub 2015 Feb 20. PMID: 25700239.
  103. Urakawa H, Yonemoto T, Matsumoto S, Takagi T, Asanuma K, Watanuki M, Takemoto A, Naka N, Matsumoto Y, Kawai A, Kunisada T, Kubo T, Emori M, Hiraga H, Hatano H, Tsukushi S, Nishida Y, Akisue T, Morii T, Takahashi M, Nagano A, Yoshikawa H, Sato K, Kawano M, Hiraoka K, Tanaka K, Iwamoto Y, Ozaki T. Clinical outcome of primary giant cell tumor of bone after curettage with or without perioperative denosumab in Japan: from a questionnaire for JCOG 1610 study. World J Surg Oncol. 2018 Aug 8;16(1):160. doi: 10.1186/s12957-018-1459-6. PMID: 30089488; PMCID: PMC6083623.
  104. Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. doi: 10.1016/S1470-2045(19)30663-1. Epub 2019 Nov 6. PMID: 31704134.
  105. Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. 2019 Oct;139(10):1339-1349. doi: 10.1007/s00402-019-03167-x. Epub 2019 Mar 15. PMID: 30877429.
  106. Uta Dirksen 1, Bernadette Brennan 2, Marie-Cécile Le Deley High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008 J Clin Oncol. 2019 Dec 1;37(34):3192-3202. doi: 10.1200
  107. Dantonello TM, Int-Veen C, Leuschner I, Schuck A, Furtwaengler R, Claviez A, Schneider DT, Klingebiel T, Bielack SS, Koscielniak E; CWS study group; COSS study group. Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups. Cancer. 2008 Jun;112(11):2424-31. doi: 10.1002/cncr.23457. PMID: 18438777.
  108. Mitchell AD, Ayoub K, Mangham DC, Grimer RJ, Carter SR, Tillman RM. Experience in the treatment of dedifferentiated chondrosarcoma. J Bone Joint Surg Br. 2000 Jan;82(1):55-61. doi: 10.1302/0301-620x.82b1.9020. PMID: 10697315.
  109. Martin-Broto J, Cleeland CS, Glare PA, et al. Effects of Denosumab on pain and analgesic use in giant cell tumor of bone: interim results from a phase II study. Acta Oncol 2014;53:1173−9.
  110. Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. doi: 10.1016/S1470-2045(19)30663-1. Epub 2019 Nov 6. PMID: 31704134.
  111. Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumab treatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. 2019 Oct;139(10):1339-1349. doi: 10.1007/s00402-019-03167-x. Epub 2019 Mar 15. PMID: 30877429.
  112. С. В. Яковлев, Н. И. Брико, С. В. Сидоренко, Д. Н. Проценко. Программа СКАТ (СТРАТЕГИЯ КОНТРОЛЯ АНТИМИКРОБНОЙ ТЕРАПИИ) при оказании стационарной медицинской помощи. (Российские клинические рекомендации). 2018. С. 62-143.
  113. Recommendations for bone and joint prosthetic device infections in clinical practice (prosthesis, implants, osteosynthesis). 2010. С.201—205.
  114. CesariM. etal. Mesenchymalchondrosarcoma. Ananalysis of patients treatedat a singleinstitution //Tumori Journal. – 2007. –Т. 93. –№. 5. –С. 423-427.
  115. Martin-Broto J, Cleeland CS, Glare PA, et al. Effects of Denosumab on pain and analgesicuse in giant cell tumor of bone: interimresultsfrom a phase II study. Acta Oncol 2014;53:1173−9.
  116. Chawla S, Blay JY, Rutkowski P, Le Cesne A, Reichardt P, Gelderblom H, Grimer RJ, Choy E, Skubitz K, Seeger L, Schuetze SM, Henshaw R, Dai T, Jandial D, Palmerini E. Denosumab in patients withgiant-cell tumour of bone: a multicentre, open-label, phase 2 study. Lancet Oncol. 2019 Dec;20(12):1719-1729. doi: 10.1016/S1470-2045(19)30663-1. Epub 2019 Nov 6. PMID: 31704134.
  117. Luengo-Alonso G, Mellado-Romero M, Shemesh S, Ramos-Pascua L, Pretell-Mazzini J. Denosumabtreatment for giant-cell tumor of bone: a systematic review of the literature. Arch Orthop Trauma Surg. 2019 Oct;139(10):1339-1349. doi: 10.1007/s00402-019-03167-x. Epub 2019 Mar 15. PMID: 30877429.
  118. Lin P. P. et al. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma //Cancer: Interdisciplinary International Journal of the American Cancer Society. – 2007. – Т. 109. – №. 3. – С. 603-611.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*